Opus Genetics, a clinical-stage biopharmaceutical company, granted 1.1 million stock options to ten new non-executive employees as an inducement to join the company. These options, approved by the Compensation Committee and compliant with Nasdaq Listing Rule 5635(c)(4), vest over four years with a fair market exercise price. This move aims to attract talent to support Opus Genetics' development of gene therapies for inherited retinal diseases, advancing their pipeline of treatments targeting genetic causes of blindness.
Opus Genetics' recent inducement grants come as part of a competitive health sector landscape. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 03, 2026 04:11 WIB: out of 150 priced US health stocks, 48 rose and 100 fell. Notable movers include TXG (10X Genomics Inc) at USD 61.51 with a 1-day change of -12.27% and a typical hold time on Pluang of 92 days, SLS (SELLAS Life Sciences Group Inc.) at USD 8.56 down 11.48% with a 9-day hold time, and DFTX (Definium Therapeutics Inc.) at USD 32.32 down 11.04% with a 14-day hold time.
Zentalis Pharmaceuticals awarded 136,000 non-qualified stock options to four newly hired employees as an inducement to join the company, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.85, matching the stock's closing p...
Dianthus Therapeutics, a clinical-stage biotech company, granted stock options to three new non-executive employees as inducements for joining the company. The options cover 26,000 shares at an exercise price of $82.25, vesting over four years. This ...
The Federal Home Loan Bank of Atlanta announced the election of three new member directors and the re-election of one independent director to its board for 2026. Suzanne DeFerie was named Chair and Kathy McKinney Vice Chair for 2027, ensuring experie...
On November 2, USDC Treasury minted 1 billion USD Coin (USDC) tokens on the Solana blockchain within a 10-minute window, transferring them to a Circle-controlled account in four transactions of 250 million USDC each. This issuance is double the 500 m...
AAR Corp has priced $955 million of 7.125% senior notes due 2031 and $960 million of 7.375% senior notes due 2034, totaling $1.915 billion. The proceeds, along with equity issuance and credit facility borrowings, will fund its acquisition of a contro...
